Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting
|
Sartorius Stedim Biotech SA
/ Key word(s): Dividend
Aubagne, February 7, 2025 Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting
The Board of Directors of Sartorius Stedim Biotech S.A. resolved at its meeting to submit a proposal to the combined Annual Shareholders’ Meeting on March 25, 2025, to pay a dividend of 0.69 euros per share for fiscal 2024, the same amount as for the previous year. If approved, the total distributed profit would be 67.1 million euros. The dividend will be paid as from April 4, 2025. The Board of Directors also approved the decision to submit to the Annual Shareholders’ Meeting the 2024 results of Sartorius Stedim Biotech which had already been published on a preliminary basis on January 28, 2025. While the mandate of one member of the Board of Directors will expire at the closing of the 2025 Annual Shareholders’ Meeting, the Board decided upon proposal of the Remuneration and Nomination Committee to suggest Cécile Dussart and Christopher Nowers to the Annual Shareholders’ Meeting as new Board candidates. Doctor of Pharmacy Cécile Dussart serves as a Board Member and ESG committee chair of CDMO and API provider EuroAPI S.A. and is a member of the Advisory Commitee at the talent intelligence platform Neobrain. Prior, she held various management positions at the Swiss listed dermatology group Galderma and at the pharmaceutical companies Roche and Sanofi. Biochemist Christopher Nowers, CEO of the cell therapy company ONK Therapeutics, held several senior leadership roles in the biopharma industry including Kite Pharma, Bristol-Myers Squibb, and Amgen. He is also a member of the Advisory Board at CAR T cell company Autolus Therapeutics. The following four members will be proposed to the AGM for renewal: Pascale Boissel, René Fáber, Lothar Kappich and Joachim Kreuzburg. Henri Riey, member of the Board since 2007 will no longer be available for a further term and will retire from the Board at the end of the Annual Shareholders’ Meeting. Already at this point, the Board would like to thank him very much for his valuable contributions and expertise that he brought to the company during his many years of service. This media release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version. Financial calendar February 17, 2025 Publication of Annual Report March 25, 2025 Annual Shareholders’ Meeting April 16, 2025 Publication of the first quarter results January to March 2025 July 22, 2025 Publication of the half-year results January to June 2025 October 16, 2025 Publication of the nine-month results January to September 2025 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros, according to preliminary figures. Currently, more than 9,900 employees are working for customers around the globe. Visit our Newsroom and follow us on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Attachment File: 20250207_SSB_PM_Dividend_proposal_en
Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2083349 |
| End of Announcement - EQS News Service | |
|
|
2083349 07-Feb-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.